Sientra (NASDAQ:SIEN)‘s stock had its “buy” rating reissued by equities researchers at Stephens in a research report issued to clients and investors on Thursday. They currently have a $30.00 price objective on the medical instruments supplier’s stock. Stephens’ price objective indicates a potential upside of 43.61% from the company’s previous close.

Several other equities analysts also recently commented on the company. Craig Hallum started coverage on Sientra in a research note on Monday, June 4th. They issued a “buy” rating and a $23.00 price objective on the stock. Lake Street Capital upped their price objective on Sientra from $11.00 to $13.00 and gave the company a “hold” rating in a research note on Thursday, April 19th. Leerink Swann reiterated an “outperform” rating on shares of Sientra in a research note on Friday, April 20th. ValuEngine upgraded Sientra from a “hold” rating to a “buy” rating in a research note on Saturday, April 21st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $18.00 price objective on shares of Sientra in a research note on Thursday, April 19th. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $21.29.

Sientra stock traded down $0.13 during trading on Thursday, hitting $20.89. The stock had a trading volume of 278,337 shares, compared to its average volume of 351,902. Sientra has a 1 year low of $8.79 and a 1 year high of $26.79. The company has a current ratio of 3.06, a quick ratio of 0.71 and a debt-to-equity ratio of 0.27. The company has a market cap of $619.15 million, a price-to-earnings ratio of -7.41 and a beta of -0.92.

Sientra (NASDAQ:SIEN) last posted its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.04). Sientra had a negative net margin of 131.16% and a negative return on equity of 151.47%. The firm had revenue of $17.55 million during the quarter, compared to analysts’ expectations of $15.30 million. equities research analysts forecast that Sientra will post -2.84 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the business. United Services Automobile Association purchased a new stake in shares of Sientra during the second quarter worth $3,937,000. Cortina Asset Management LLC purchased a new stake in shares of Sientra during the second quarter worth $6,516,000. Janus Henderson Group PLC purchased a new stake in shares of Sientra during the second quarter worth $20,375,000. BlackRock Inc. lifted its position in shares of Sientra by 94.3% during the second quarter. BlackRock Inc. now owns 1,490,587 shares of the medical instruments supplier’s stock worth $29,081,000 after acquiring an additional 723,279 shares in the last quarter. Finally, Mutual of America Capital Management LLC purchased a new stake in shares of Sientra during the second quarter worth $1,198,000. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Further Reading: Earnings Per Share (EPS) Explained

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.